MARKET

BCTX

BCTX

Briacell Therapeutics Corp
NASDAQ
2.670
+0.130
+5.12%
Closed 16:00 03/27 EDT
OPEN
2.600
PREV CLOSE
2.540
HIGH
2.680
LOW
2.490
VOLUME
85.18K
TURNOVER
0
52 WEEK HIGH
7.75
52 WEEK LOW
2.190
MARKET CAP
42.67M
P/E (TTM)
-3.2793
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BCTX last week (0318-0322)?
Weekly Report · 2d ago
BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024
BriaCell Therapeutics reported earnings per share of -71 cents for the second quarter of 2024. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports. BriaCell reported results for second quarter 2024.
Investorplace · 03/19 10:52
Briacell Therapeutics Corp reports results for the quarter ended in January - Earnings Summary
Briacell Therapeutics Corp reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 71 cents per share. The lone analyst forecast was for a loss of 20 cents. Briacell's shares had fallen by 49.6% this quarter.
Reuters · 03/18 22:43
Weekly Report: what happened at BCTX last week (0311-0315)?
Weekly Report · 03/18 11:16
Weekly Report: what happened at BCTX last week (0304-0308)?
Weekly Report · 03/11 11:12
Briacell Therapeutics Corp <BCT.TO> expected to post a loss of 20 cents a share - Earnings Preview
Briacell Therapeutics Corp BCT.TO expected to post a loss of 20 cents a share. The one available analyst rating on the shares is "buy" Wall Street's median 12-month price target for the company is $18.00. The company is expected to report results on March 11.
Reuters · 03/08 21:27
BriaCell Partners to Propel Cancer Vaccine Development
BriaCell Therapeutics has entered a significant agreement with the University of Texas MD Anderson Cancer Center to develop cancer vaccines. The company is developing immunotherapies for breast and prostate cancer. BriaCell has a market capitalization of TSE:BCT.
TipRanks · 03/07 13:37
BriaCell Receives And Executes Letter Of Intent To Advance Clinical Development Of Breast And Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of BriaCell's novel off-the-shelf personalized cancer vaccines, marks a major milestone for the company. University of Texas MD Anderson Cancer Center to develop Bria-OTS+ in advanced breast cancer and prostate cancer.
Benzinga · 03/07 13:02
More
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Webull offers Briacell Therapeutics Corp stock information, including NASDAQ: BCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCTX stock methods without spending real money on the virtual paper trading platform.